Demographic Data of Controls and iRBD Patients (Cohorts A and B)
| iRDBRP identification (cohort A) | iRBDRP validation (cohort B) | |||||
| Variable | Controls | iRBD | P* | Controls | iRBD | P* |
| n | 19 | 21 | 13 | 9 | ||
| Age (y)† | 62.4 ± 7.5 (43–70) | 61.9 ± 5.4 (50–70) | 0.82 | 61.3 ± 8.6 (52–78) | 64.2 ± 6.3 (56–78) | 0.40 |
| Sex (male/female) | 9/10 | 18/3 | 0.010 | 9/4 | 8/1 | 0.36 |
| MoCA | 29 (27–30) | 27 (25.5–28) | 0.003 | 30 (28.5–30)‡ | 28 (27–29) | |
| UPDRS-III | 0 (0–1) | 2 (1–4) | 0.002 | NA | 2 (0–2) | |
| Age at onset RBD† | 55.0 ± 7.1 (37–67) | 60.8 ± 6.0 (52–73) | ||||
| iRBD duration (y) | 6 (3.5–8.0) | 4 (1.0–5.0) | ||||
| iRBDRP z scores | 0 ± 1 | 1.7 ± 1.2 | <0.0001 | 0.6 ± 1.1 | 1.5 ± 0.8 | 0.04 |
↵* Controls versus iRBD patients; t test for age; χ2 for sex, Mann–Whitney U test for UPDRS and MoCA.
↵† Mean ± SD, with range in parentheses.
↵‡ In B controls, Mini-Mental State Examination (MMSE; maximum of 30 points) was used instead of MoCA.
MoCA = Montreal Cognitive Assessment; UPDRS-III = part 3 of the Unified Parkinson Disease Rating Scale (2003 version); NA = not available.
Values are median, with interquartile range in parentheses.